The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats
- 13 March 2004
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 175 (3) , 310-318
- https://doi.org/10.1007/s00213-004-1827-5
Abstract
Rationale Recent studies have shown that metabotropic glutamate receptor 5 (mGluR5) can modulate N-methyl-d-aspartate (NMDA) receptor function in vivo. For example, the mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) can potentiate PCP (phencyclidine)-evoked hyperactivity and PCP-induced disruptions in pre-pulse inhibition (PPI) in rats. Objective To extend these previous behavioral findings and determine whether the mGluR5 antagonist MPEP can modulate the disruptions in learning and memory induced by PCP in rats. Methods The effects of MPEP, alone and in combination with PCP, were evaluated in rats trained to perform a repeated acquisition procedure (learning) or a delayed non-matching to position (DNMTP) radial maze task (spatial memory). Results In the repeated acquisition task, MPEP (0–10 mg/kg, IP) dose-dependently decreased response rates but had no effect on response accuracy. In contrast, PCP (0.625–1.25 mg/kg, SC) reduced response rate and response accuracy in a dose-dependent manner. Although MPEP (10 mg/kg, IP) had no effect when administered alone, the mGluR5 antagonist potentiated the disruptions in learning induced by a low dose of PCP (0.625 mg/kg, SC). In the DNMTP maze task, MPEP (0–10 mg/kg, IP) had no effect on spatial memory, whereas PCP (1.25–2.5 mg/kg, SC) produced a dose-dependent disruption. MPEP (10 mg/kg, IP) potentiated the impairments in memory induced by PCP (1.25 mg/kg, SC). Conclusion The mGluR5 antagonist, MPEP, potentiated the disruptions in learning and memory induced by PCP. These behavioral data extend previous behavioral findings and further suggest that mGluR5 can modulate NMDA receptor function in vivo.Keywords
This publication has 68 references indexed in Scilit:
- Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonistNeuropharmacology, 2002
- [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo CharacterizationThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Effects of Ketamine in Normal and Schizophrenic VolunteersPublished by Springer Nature ,2001
- Selective mGluR5 antagonists MPEP and SIB‐1893 decrease NMDA or glutamate‐mediated neuronal toxicity through actions that reflect NMDA receptor antagonismBritish Journal of Pharmacology, 2000
- Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophreniaInternational Journal of Neuropsychopharmacology, 1998
- Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free SchizophrenicsNeuropsychopharmacology, 1997
- Activation of group I mG1uRs potentiates NMDA responses in rat hippocampal slicesNeuroscience Letters, 1996
- Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brainJournal of Comparative Neurology, 1995
- The effect of NMDA antagonists in the radial arm maze task with an interposed delayPharmacology Biochemistry and Behavior, 1990